A. D. Beadell Investment Counsel Inc. Has $2.71 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

A. D. Beadell Investment Counsel Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 8.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,985 shares of the medical instruments supplier’s stock after selling 1,000 shares during the period. Becton, Dickinson and accounts for 2.3% of A. D. Beadell Investment Counsel Inc.’s holdings, making the stock its 14th largest holding. A. D. Beadell Investment Counsel Inc.’s holdings in Becton, Dickinson and were worth $2,708,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Becton, Dickinson and by 1.3% in the first quarter. Vanguard Group Inc. now owns 24,487,340 shares of the medical instruments supplier’s stock valued at $6,513,633,000 after acquiring an additional 310,974 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Becton, Dickinson and by 4.2% in the 4th quarter. BlackRock Inc. now owns 20,694,679 shares of the medical instruments supplier’s stock valued at $5,204,300,000 after purchasing an additional 828,789 shares in the last quarter. State Street Corp boosted its stake in shares of Becton, Dickinson and by 3.9% in the 4th quarter. State Street Corp now owns 12,705,205 shares of the medical instruments supplier’s stock valued at $3,195,105,000 after purchasing an additional 480,684 shares in the last quarter. Wellington Management Group LLP boosted its position in Becton, Dickinson and by 0.3% during the 1st quarter. Wellington Management Group LLP now owns 11,347,452 shares of the medical instruments supplier’s stock valued at $3,018,423,000 after buying an additional 34,821 shares during the period. Finally, Parnassus Investments LLC raised its holdings in Becton, Dickinson and by 1.2% in the 1st quarter. Parnassus Investments LLC now owns 5,156,630 shares of the medical instruments supplier’s stock worth $1,371,664,000 after purchasing an additional 58,966 shares in the last quarter. Institutional investors and hedge funds own 86.74% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of a number of analyst reports. Stifel Nicolaus reduced their price objective on shares of Becton, Dickinson and from $290.00 to $280.00 in a research note on Monday, July 18th. The Goldman Sachs Group lifted their price target on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. Wells Fargo & Company upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price objective on the stock in a research report on Friday, June 24th. Morgan Stanley reduced their price target on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating on the stock in a research report on Friday, July 15th. Finally, Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $265.00 to $235.00 in a research report on Monday, July 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and currently has an average rating of “Hold” and an average target price of $277.63.

Insider Activity at Becton, Dickinson and

In other Becton, Dickinson and news, EVP David Hickey sold 475 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $265.00, for a total value of $125,875.00. Following the completion of the sale, the executive vice president now directly owns 3,331 shares of the company’s stock, valued at approximately $882,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Becton, Dickinson and news, EVP David Hickey sold 475 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $265.00, for a total value of $125,875.00. Following the completion of the sale, the executive vice president now directly owns 3,331 shares of the company’s stock, valued at approximately $882,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Samrat S. Khichi sold 9,185 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total value of $2,392,141.40. Following the sale, the executive vice president now directly owns 5,928 shares of the company’s stock, valued at $1,543,888.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,160 shares of company stock valued at $5,036,751. 0.50% of the stock is owned by insiders.

Becton, Dickinson and Stock Performance

Becton, Dickinson and stock traded down $5.30 during mid-day trading on Friday, hitting $231.89. The company had a trading volume of 37,465 shares, compared to its average volume of 968,418. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.58. Becton, Dickinson and Company has a 12-month low of $231.46 and a 12-month high of $280.62. The company’s fifty day moving average is $252.37 and its 200-day moving average is $253.93. The company has a market capitalization of $66.14 billion, a price-to-earnings ratio of 40.89, a P/E/G ratio of 3.12 and a beta of 0.57.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The firm had revenue of $4.64 billion for the quarter, compared to analyst estimates of $4.47 billion. During the same quarter last year, the firm posted $2.74 EPS. The business’s revenue was down 5.1% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post 11.31 EPS for the current year.

Becton, Dickinson and Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be paid a $0.87 dividend. This represents a $3.48 annualized dividend and a yield of 1.50%. The ex-dividend date of this dividend is Thursday, September 8th. Becton, Dickinson and’s dividend payout ratio is currently 60.00%.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.